Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

lung illustration
Merck announced Phase III interim data for Keytruda in adjuvant NSCLC • Source: Shutterstock

Merck & Co., Inc. is jumping into the potentially lucrative market of adjuvant treatment of non-small cell lung cancer (NSCLC) with new Phase III data for Keytruda (pembrolizumab) that sets the PD-1 inhibitor up as a competitor to Roche Holding AG’s PD-L1 inhibitor, Tecentriq (atezolizumab). However, there is some question about how closely the two drugs will compete based on the magnitude of Keytruda’s benefit in patients with high PD-L1 expression, despite the drug’s efficacy in a broader range of patients.

Merck & Co. announced interim data on 17 March from the KEYNOTE-091 trial showing a statistically significant improvement on the...

Welcome to Scrip

Create an account to read this article

More from Anticancer

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

More from Therapy Areas

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.